肺癌组织MTA1、VEGF-C表达变化及与患者临床病理特征、预后关系  

Expression of MTA1 and VEGF-C in lung cancer tissues and their relationship with clinicopathological features and prognosis

作　　者：赵丽霞[1] 任成波 马峰[1] 李占林[3] 赵峻峰[1] ZHAO Lixia;REN Chengbo;MA Feng;LI Zhanlin;ZHAO Junfeng(Internal Medicine-Oncology,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China;Department of the Radiotherapy,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China;Department of the Traditional Chinese Medicine,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China)

机构地区：[1]河北北方学院附属第一医院肿瘤内科,河北张家口075000 [2]河北北方学院附属第一医院放疗科,河北张家口075000 [3]河北北方学院附属第一医院中医科,河北张家口075000

出　　处：《广东药科大学学报》2022年第1期103-108,共6页Journal of Guangdong Pharmaceutical University

基　　金：河北省卫生和计生委员会2018年医学科学研究重点课题计划项目(20180853)。

摘　　要：目的探究转移相关基因1(MTA1)、血管内皮生长因子C(VEGF-C)在肺癌组织中的表达变化及与患者临床病理特征、预后关系。方法收集我院2016年1月-2018年9月经病理确诊的200例肺癌组织标本及50例癌旁正常组织标本,采用免疫组化法检测组织MTA1、VEGF-C蛋白表达情况。分析MTA1、VEGF-C在不同病理类型肺癌组织表达差异以及与患者临床病理特征关系,采用Spearman相关分析法探究MTA1、VEGF-C表达相关性,绘制Kaplan-Meier生存曲线探究MTA1、VEGF-C表达与患者预后关系。结果肺癌组织MTA1、VEGF-C表达阳性率分别为70.50%、66.00%,高于癌旁正常组织的26.00%、42.00%(P<0.05)。MTA1、VEGF-C在不同病理类型肺癌组织中表达差异均无统计学意义(P>0.05)。肺癌组织MTA1阳性表达与患者分化程度低、TNM分期高、淋巴结转移有关(P<0.05),VEGF-C阳性表达与患者分化程度低、TNM分期高、脉管浸润、淋巴结转移有关(P<0.05)。肺癌组织MTA1与VEGF-C表达呈正相关(P<0.05)。随访截至2021年9月,肺癌组织MTA1阳性表达者无进展生存期为(16.22±8.87)月,3年无进展生存率5.67%,低于阴性者的(24.49±11.25)月、23.73%(Log-rank χ^(2)=22.522,P<0.001);VEGF-C阳性表达者无进展生存期为(16.99±9.58)月,3年无进展生存率7.09%,均低于阴性者的(21.90±11.00)月、20.34%(Log-rank χ^(2)=7.762,P=0.005)。结论MTA1、VEGF-C在肺癌组织中均呈异常表达,与病理类型无关,但二者可能协同参与肺癌疾病发生发展,影响患者预后。Objective To explore the expression of metastasis-associated gene 1(MTA1)and vascular endothelial growth factor C(VEGF-C)in lung cancer tissues and their relationship with clinicopathological features and prognosis.Methods 200 lung cancer tissue samples and 50 adjacent normal tissue samples diagnosed pathologically in our hospital from January 2016 to September 2018 were collected.The expressions of MTA1 and VEGF-C were detected by immunohistochemistry.The expression differences of MTA1 and VEGF-C in different pathological types of lung cancer and their relationship with clinicopathological characteristics were analyzed.Spearman correlation analysis was used to explore the correlation between the expression of MTA1 and VEGF-C,and Kaplan Meier survival curve was drawn to explore the relationship between the expression of MTA1 and VEGF-C and the prognosis of patients.Results The positive rates of MTA1 and VEGF-C in lung cancer tissues were 70.50%and 66.00%respectively,which were higher than 26.00%in adjacent normal tissues 42.00%(P<0.05).There was no significant difference in the expression of MTA1 and VEGF-C in different pathological types of lung cancer(P>0.05).The positive expression of MTA1 in lung cancer was related to low differentiation,high TNM stage and lymph node metastasis(P<0.05),and the positive expression of VEGF-C was related to low differentiation,high TNM stage,vascular invasion and lymph node metastasis(P<0.05).There was a positive correlation between MTA1 and VEGF-C expression in lung cancer tissues(P<0.05).Up to September 2021,the progression free survival time of MTA1 positive lung cancer tissues was(16.22±8.87)months,and the 3-year progression free survival rate was 5.67%,which was lower than(24.49±11.25)months and 23.73%of patients with negative expression(Log-rank χ^(2)=22.522,P<0.001).The progression free survival time of VEGF-C positive patients was(16.99±9.58)months,and the 3-year progression free survival rate was 7.09%,which was lower than that of negative patients(21.90±11.00)mont

关 键 词：肺癌 转移相关基因1 血管内皮生长因子C 免疫组织化学 预后 

分 类 号：R734.2[医药卫生—肿瘤]